Aspergillosis in the African Grey Parrot — Management Guide

Comprehensive, practical guide to diagnosing and managing aspergillosis in African Grey parrots, including risk factors, diagnostics (CT/endoscopy/serology), antifungal therapy, and environment control.

Quick Overview

• What it is: Aspergillosis is a fungal infection (usually Aspergillus fumigatus) that most commonly affects the respiratory tract — air sacs, lungs and sinuses — of birds.
• Who's at risk: Captive African Grey parrots (Psittacus erithacus) are predisposed because of stress sensitivity, frequent exposure to indoor mold, and conditions that depress immunity (poor diet, chronic disease, or corticosteroid use).
• Prognosis: Highly variable. Localized lesions (single granulomas or limited air-sac disease) have the best chance of a favorable outcome with combined medical and, when needed, surgical therapy. Diffuse, invasive disease carries a guarded to poor prognosis despite treatment.

Why this matters for African Greys

African Greys are intelligent, long-lived parrots that commonly live indoors and may be exposed to indoor molds (seed hulls, damp bedding, potted plants) and chronic stressors. Aspergillosis is one of the most important infectious respiratory diseases in captive psittacines and a leading cause of chronic respiratory disease and death when not recognized early.

Pathophysiology — explained simply

Aspergillus spores are ubiquitous in the environment and are continuously inhaled. In healthy birds the spores are removed by mucociliary clearance and immune defenses in the respiratory tract. When inhaled burden is high or the bird's local or systemic immunity is impaired, spores can germinate on respiratory mucosa and within air sacs. The fungus forms branching hyphae that invade tissue and trigger granulomatous inflammation and necrosis. In severe cases the infection spreads through the lungs and air sacs, reducing gas-exchange surface and producing respiratory failure.

Breed-specific risk factors and prevalence

• African Greys appear over-represented among pet psittacines with aspergillosis in clinic populations — likely because they are commonly kept indoors, are sensitive to stress, and often receive seed-heavy diets that can be moldy.
• Risk factors: Poor ventilation, high humidity, moldy food, damp bedding, overcrowding, recent transport or boarding, underlying chronic illness, immunosuppressive drugs (especially corticosteroids), poor nutrition (vitamin A deficiency), and viral infections.
• Prevalence: True prevalence in African Greys is not precisely known and varies with husbandry. Clinical series and necropsy studies identify aspergillosis as a frequent cause of respiratory disease in captive parrots (see sources below).

Typical signs progress from non-specific to respiratory and systemic:

• Early/subclinical: Mild lethargy, reduced appetite, subtle weight loss, decreased vocalization.
• Localized respiratory disease: Nasal discharge, increased respiratory noise, voice change, tail bobbing, exercise intolerance.
• Advanced/diffuse disease: Open-mouth breathing, marked respiratory effort, cyanosis, collapse, sudden death in acute fulminant cases.
• Other signs: Sinus swelling, ocular discharge, poor feather condition, and secondary bacterial infections.

• Acute/fulminant (rapidly progressive respiratory distress)
• Chronic/localized (single granuloma, limited air-sac disease)
• Chronic/diffuse (multifocal air-sac and pulmonary involvement)

Goal: confirm fungal infection, define extent, and obtain samples for culture/histology.

1) Physical exam and baseline tests

• Full physical, body weight, respiratory rate/character.
• Routine bloodwork (CBC, plasma biochemistry) — may reveal heterophilia or non-specific changes; liver values help guide drug choice and monitoring.

• Radiographs: Readily available but often insensitive early. Can show air-sac opacity, nodules, or increased perihilar or coelomic densities.
• CT (computed tomography): The most sensitive anatomic imaging for air sacs, syrinx, sinuses and pulmonary parenchyma. CT better delineates extent and can guide surgery/endoscopy.

• Direct visualization is a major advantage — you can see granulomas or plaques and obtain biopsy or lavage samples.
• Endoscopic-guided tissue biopsy for histopathology is diagnostic (see fungal hyphae and granulomatous inflammation).

• Cytology of lavage samples may reveal hyphae. Culture identifies Aspergillus species (A. fumigatus most common) and allows antifungal susceptibility testing in selected cases.

• Antibody tests and galactomannan antigen assays exist but have variable sensitivity and specificity in birds; they can support diagnosis but rarely substitute for direct visualization/biopsy.
• PCR-based assays can detect fungal DNA from tissues but are not universally available.

• Refer to an avian specialist or veterinary hospital for CT, endoscopy, or advanced surgery/treatment planning when infection is suspected or confirmed.

Principles: (1) reduce fungal burden (debridement, topical therapy), (2) systemic antifungal therapy to eradicate residual infection, (3) correct predisposing factors and support the bird.

Medical (systemic antifungals)

• Voriconazole (triazole): Often first-line for invasive avian aspergillosis because of good tissue penetration and activity against A. fumigatus.

• Terbinafine (allylamine): Frequently used as an adjunct with an azole due to potential synergistic activity and good tissue levels in air sacs.

• Itraconazole and posaconazole: Alternatives; itraconazole (5–10 mg/kg PO q12–24h) is historically common, posaconazole is expensive but useful for resistant infections.

Duration of therapy

• Long: therapy commonly extends for many weeks to months. Typical minimum is 6–12 weeks and often continues 4–6 weeks beyond clinical resolution and normalization (or marked improvement) of imaging/endoscopy. Some cases need many months of treatment.

• Endoscopic debridement: Surgical or endoscopic removal of granulomas and necrotic tissue reduces fungal burden and improves response to systemic drugs.
• Topical antifungal irrigation/instillation: Under anesthesia, air sacs or sinus cavities can be irrigated with clotrimazole or amphotericin B solutions; clotrimazole impregnated sponges or gels placed into infected sinuses/air sacs have been used successfully for focal disease.
• Nebulization: Saline nebulization is supportive. Nebulized antifungals (e.g., amphotericin B) have been used as adjuncts but are less consistently effective as systemic therapy.

• Nutrition optimization (vitamin A, balanced diet), fluid therapy if dehydrated, heat support, oxygen therapy for respiratory distress, and treatment of secondary bacterial infections as indicated.

• Clinical: Frequent rechecks early (1–2 weeks) then monthly. Track body weight, respiratory signs, activity, and appetite.
• Laboratory: Baseline and repeat biochemistry (liver enzymes) every 2–4 weeks while on systemic antifungals.
• Imaging/endoscopy: Reassess with CT or endoscopy to document lesion resolution; frequency individualized — often 6–12 weeks after starting therapy, sooner if clinically indicated.
• Culture/histology: Repeat sampling if relapse or poor response.

• Prognosis depends on extent and location. Localized, accessible granulomas have the best outcomes when debrided and followed with systemic therapy (reported success rates vary — many case series report improved outcomes with combined therapy; diffuse disease has a guarded to poor prognosis).
• Even with successful therapy, relapses are common because spores persist in the environment and immune defects may persist.
• Quality of life: Many birds return to good function after effective treatment of localized disease. For diffuse disease, consider the bird's comfort, oxygen needs, and the practicality of long-term therapy when making decisions.

• Environment:

• Diet and husbandry:

• Quarantine:

• Air quality:

When to see your vet urgently

Seek immediate veterinary care if your African Grey shows any of the following:

• Open-mouth breathing, severe respiratory effort or panting
• Blue/purple mucous membranes (cyanosis) or collapse
• Sudden marked lethargy, inability to stand, or seizures
• Rapid weight loss or refusal to eat for >24 hours

• Antifungal drugs have potential side effects (notably hepatotoxicity). Baseline bloodwork and regular monitoring are essential.
• Never start or adjust antifungal therapy without veterinary guidance — dosing varies with species and individual factors; drug interactions occur (e.g., voriconazole interactions) and dosing for birds differs from mammals.

Aspergillosis is a common and potentially serious respiratory infection in African Grey parrots. Early recognition, accurate diagnosis (CT and endoscopic biopsy when possible), combined local debridement and systemic antifungal therapy (voriconazole and—often—terbinafine), and environmental control of mold exposure provide the best chance for recovery. Long treatment courses, careful monitoring for drug toxicity, and attention to husbandry are essential.

Primary citation

Merck Veterinary Manual — Aspergillosis in Birds: https://www.merckvetmanual.com/avian/respiratory-system/aspergillosis-in-birds

Other resources

• Journal of Avian Medicine and Surgery review articles on aspergillosis and antifungal therapy
• Specialty avian/veterinary internal medicine consultations (ACVIM diplomates, avian specialists)

Frequently Asked Questions